Mumbai-based pharmaceutical giant Cipla announced on Wednesday that it has received final approval from the US Food and Drug Administration (USFDA) to market Lanreotide Injection, a generic medication used to treat acromegaly and certain types of neuroendocrine tumors.
Cipla’s Lanreotide Injection is a therapeutic equivalent to the Somatuline Depot Injection, which is widely used for the treatment of patients with acromegaly and gastroenteropancreatic neuroendocrine tumors. The company plans to offer the injection in multiple strengths, providing a cost-effective alternative to the existing medication.
The approval marks a significant milestone for Cipla, enabling it to enter a lucrative market with a proven therapeutic solution. According to IQVIA (IMS Health), Somatuline Depot generated sales of approximately USD 898 million in the US for the 12-month period ending March 2024.
“This approval is a testament to our commitment to providing high-quality, affordable medications to patients,” Cipla said in a statement. “We are excited to bring our Lanreotide Injection to market, offering a reliable and cost-effective treatment option for patients with acromegaly and gastroenteropancreatic neuroendocrine tumors.”
The approval from the USFDA allows Cipla to expand its footprint in the US market, further solidifying its position as a leading global pharmaceutical company.
